Jing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Chen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Lei Cheng
Department of Cariology and Endodontics, State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University., Cheng Du, China
4 shared publications Xuedong Zhou
State Key Laboratory of Oral Diseases & Department of Cariology and Endodontics, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
4 shared publicationsMeixuan Chen
2 shared publicationsWei Zhao
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China
2 shared publicationsYuxuan Li
School of Stomatology Dalian Medical University Dalian Liaoning China
2 shared publicationsZhiqiang Luo
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Sichuan University Chengdu Sichuan China
2 shared publications
Latest Publications
- Open Access
- 28 January 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (2) , 62
Photothermal therapy synergizes with CD47 blockade by inducing calreticulin exposure and remodeling the tumor extracellular matrix in oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC) overexpresses CD47, enabling immune evasion via a "don't eat me" signal to macrophages. Although CD47 blockade shows promise, its efficacy is limited due to a lack of "eat me" signal and contact between macrophages and tumor cells. This study aimed to evaluate the synergistic anti-tumor effect of combining photothermal therapy (PTT) with CD47 blockade in OSCC and elucidate the underlying mechanisms. In vitro phagocytosis was assessed by flow cytometry. In vivo anti-tumor efficacy was measured by tumor growth inhibition. Mechanistic studies included detection of immunogenic cell death (ICD) markers (ATP, HMGB1, calreticulin (CRT)), confocal microscopy for CRT-macrophage co-localization, analysis of ECM component expression, and immunofluorescence for macrophage infiltration. The combination of PTT and CD47 blockade significantly enhanced macrophage phagocytosis in vitro and strongly inhibited tumor growth in vivo. PTT induced ICD, as evidenced by the release of ATP and HMGB1, and the exposure of CRT on the cell membrane. Confocal microscopy confirmed co-localization of CRT-expressing tumor cells with macrophages. Furthermore, PTT down-regulated ECM components at transcriptional and protein levels, which correlated with increased macrophage infiltration into tumors. PTT synergizes with CD47 blockade primarily by inducing CRT-dependent pro-phagocytic signaling to provide the "eat me" signal. In parallel, PTT downregulates ECM components, enabling the essential "come near me" process that facilitates macrophage infiltration into tumors. This dual approach significantly improves the macrophage based anti-tumor efficacy of CD47 blockade.
- 28 January 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (2) , 62
Open AccessPhotothermal therapy synergizes with CD47 blockade by inducing calreticulin exposure and remodeling the tumor extracellular matrix in oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC) overexpresses CD47, enabling immune evasion via a "don't eat me" signal to macrophages. Although CD47 blockade shows promise, its efficacy is limited due to a lack of "eat me" signal and contact between macrophages and tumor cells. This study aimed to evaluate the synergistic anti-tumor effect of combining photothermal therapy (PTT) with CD47 blockade in OSCC and elucidate the underlying mechanisms. In vitro phagocytosis was assessed by flow cytometry. In vivo anti-tumor efficacy was measured by tumor growth inhibition. Mechanistic studies included detection of immunogenic cell death (ICD) markers (ATP, HMGB1, calreticulin (CRT)), confocal microscopy for CRT-macrophage co-localization, analysis of ECM component expression, and immunofluorescence for macrophage infiltration. The combination of PTT and CD47 blockade significantly enhanced macrophage phagocytosis in vitro and strongly inhibited tumor growth in vivo. PTT induced ICD, as evidenced by the release of ATP and HMGB1, and the exposure of CRT on the cell membrane. Confocal microscopy confirmed co-localization of CRT-expressing tumor cells with macrophages. Furthermore, PTT down-regulated ECM components at transcriptional and protein levels, which correlated with increased macrophage infiltration into tumors. PTT synergizes with CD47 blockade primarily by inducing CRT-dependent pro-phagocytic signaling to provide the "eat me" signal. In parallel, PTT downregulates ECM components, enabling the essential "come near me" process that facilitates macrophage infiltration into tumors. This dual approach significantly improves the macrophage based anti-tumor efficacy of CD47 blockade.
- Open Access
- 1 September 2025
- Published by KEAI Publishing in Space Habitation
- Vol. 1 (2)
Oral health in space: Understanding impacts of microgravity and developing countermeasures for space applications
- 1 September 2025
- Published by KEAI Publishing in Space Habitation
- Vol. 1 (2)
Open AccessOral health in space: Understanding impacts of microgravity and developing countermeasures for space applications
- Open Access
- 16 August 2025
- Published by Springer Nature in BMC Oral Health
- Vol. 25 (1) , 1332
A novel selective medium Sucrose-Bacitracin agar 10 for accurate isolation and identification of Streptococcus mutans
To develop and evaluate Sucrose-Bacitracin agar with 10% sucrose (SB-10), a novel selective medium designed to enhance the isolation and identification of Streptococcus mutans, a key cariogenic pathogen in dental caries. SB-10 was compared to Mitis Salivarius Bacitracin agar with 20% sucrose (MSB-20) for its ability to support S. mutans growth, promote distinctive colony morphology, and differentiate it from other oral bacteria. Sugar particle formation was assessed using wild-type and mutant strains of S. mutans lacking glucosyltransferases B and C (GtfB and GtfC). Liquid chromatography was performed to characterize the sugar particles around colonies. The specificity and clinical utility of SB-10 were further assessed by culturing clinical saliva samples and confirming S. mutans colonies via 16S rRNA sequencing. SB-10 supported robust S. mutans growth with larger colonies and distinctive sugar particle formation compared to MSB-20. GtfB and GtfC were essential for sugar particle deposition around colonies. SB-10 demonstrated high specificity by suppressing the growth of non-target oral bacteria and accurately isolating S. mutans from clinical saliva samples, with all colonies confirmed as S. mutans via 16S rRNA sequencing. SB-10 is a novel selective medium that enhances the isolation and identification of S. mutans, characterized by unique sugar particles deposition and colony morphology.
- 16 August 2025
- Published by Springer Nature in BMC Oral Health
- Vol. 25 (1) , 1332
Open AccessA novel selective medium Sucrose-Bacitracin agar 10 for accurate isolation and identification of Streptococcus mutans
To develop and evaluate Sucrose-Bacitracin agar with 10% sucrose (SB-10), a novel selective medium designed to enhance the isolation and identification of Streptococcus mutans, a key cariogenic pathogen in dental caries. SB-10 was compared to Mitis Salivarius Bacitracin agar with 20% sucrose (MSB-20) for its ability to support S. mutans growth, promote distinctive colony morphology, and differentiate it from other oral bacteria. Sugar particle formation was assessed using wild-type and mutant strains of S. mutans lacking glucosyltransferases B and C (GtfB and GtfC). Liquid chromatography was performed to characterize the sugar particles around colonies. The specificity and clinical utility of SB-10 were further assessed by culturing clinical saliva samples and confirming S. mutans colonies via 16S rRNA sequencing. SB-10 supported robust S. mutans growth with larger colonies and distinctive sugar particle formation compared to MSB-20. GtfB and GtfC were essential for sugar particle deposition around colonies. SB-10 demonstrated high specificity by suppressing the growth of non-target oral bacteria and accurately isolating S. mutans from clinical saliva samples, with all colonies confirmed as S. mutans via 16S rRNA sequencing. SB-10 is a novel selective medium that enhances the isolation and identification of S. mutans, characterized by unique sugar particles deposition and colony morphology.
- 20 January 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (7) , 2272-2294
Exploring the multifaceted roles of metal–organic frameworks in ecosystem regulation
This review provides a comprehensive analysis on the applications of various MOFs in both microbial eradication and protection, emphasizing their potential as promising smart materials in the field of ecosystem regulation.
- 20 January 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (7) , 2272-2294
Exploring the multifaceted roles of metal–organic frameworks in ecosystem regulation
This review provides a comprehensive analysis on the applications of various MOFs in both microbial eradication and protection, emphasizing their potential as promising smart materials in the field of ecosystem regulation.
- Top Cited PapersOpen Access
- 29 November 2024
- Published by Elsevier in Redox Biology
- Vol. 79, 103451
Revolutionizing oral care: Reactive oxygen species (ROS)-Regulating biomaterials for combating infection and inflammation
- 29 November 2024
- Published by Elsevier in Redox Biology
- Vol. 79, 103451
Top Cited PapersOpen AccessRevolutionizing oral care: Reactive oxygen species (ROS)-Regulating biomaterials for combating infection and inflammation
- 17 September 2024
- Published by Wiley in International Endodontic Journal
- Vol. 57 (12) , 1700-1716
Efficacy of laser adjuvant therapy in the management of post‐operative endodontic pain: A systematic review and meta‐analysis
Background: Postoperative endodontic pain (PEP) is crucial in clinical practice. Recently, the effects of various laser adjuvant therapies in endodontic treatments have been widely evaluated. However, as a virtually side‐effect‐free treatment, its effect on postoperative pain management during endodontic treatment remains controversial.Objectives: This review aimed to compare the efficacy of laser adjuvant therapy for pain management after endodontic treatment.Method: The Cochrane Library, PubMed, Embase, Scopus and Web of Science databases were systematically searched for articles published until 12 February 2023. The risk of bias in the included studies was evaluated based on the Cochrane risk‐of‐bias assessment tool. Data on continuous outcomes of visual analogue scale pain scores are expressed as standard mean difference (SMD) and dichotomous outcomes of pain prevalence as relative risk (RR).Results: We included 22 studies, of which 15 enrolled 892 patients with visual analogue scale pain scores and 7 enrolled 422 patients with pain prevalence. Of the 22 studies, seven studies had a low risk of bias, 10 had a moderate risk of bias and 5 had a high risk of bias. For pain level, the pooled outcomes indicated reduced pain scores in all laser adjuvant therapy, including low‐level laser therapy (SMD = −0.86 [95% CI: −1.16, −0.55] in 24 h and SMD = −0.64 [95% CI: −0.84, −0.43] in 48 h), diode laser therapy (SMD = −0.27 [95% CI: −0.50, −0.04] in 48 h) and photodynamic therapy (SMD = −1.12 [95% CI: −2.18, −0.05] in 24 h). For postoperative pain incidence, a significant correlation was observed with reduced pain incidence rates in the photodynamic therapy group (pooled RR = 0.47 [95% CI: 0.31, 0.72]) but not in the low‐level laser therapy group (RR = 0.89 [95% CI: 0.30, 2.70] at 12 h and RR = 0.57 [95% CI: 0.09, 3.72] at 24 h).Conclusions: High‐quality evidence suggests that laser adjuvant therapies such as low‐level laser therapy, diode laser therapy and photodynamic therapy have a positive impact on reducing postoperative endodontic pain intensity. However, the differences in PEP management effects between laser therapies are unknown, and no significant differences were observed among the subgroups.Registration: CRD 42023402872 (PROSPERO).
- 17 September 2024
- Published by Wiley in International Endodontic Journal
- Vol. 57 (12) , 1700-1716
Efficacy of laser adjuvant therapy in the management of post‐operative endodontic pain: A systematic review and meta‐analysis
Background: Postoperative endodontic pain (PEP) is crucial in clinical practice. Recently, the effects of various laser adjuvant therapies in endodontic treatments have been widely evaluated. However, as a virtually side‐effect‐free treatment, its effect on postoperative pain management during endodontic treatment remains controversial.Objectives: This review aimed to compare the efficacy of laser adjuvant therapy for pain management after endodontic treatment.Method: The Cochrane Library, PubMed, Embase, Scopus and Web of Science databases were systematically searched for articles published until 12 February 2023. The risk of bias in the included studies was evaluated based on the Cochrane risk‐of‐bias assessment tool. Data on continuous outcomes of visual analogue scale pain scores are expressed as standard mean difference (SMD) and dichotomous outcomes of pain prevalence as relative risk (RR).Results: We included 22 studies, of which 15 enrolled 892 patients with visual analogue scale pain scores and 7 enrolled 422 patients with pain prevalence. Of the 22 studies, seven studies had a low risk of bias, 10 had a moderate risk of bias and 5 had a high risk of bias. For pain level, the pooled outcomes indicated reduced pain scores in all laser adjuvant therapy, including low‐level laser therapy (SMD = −0.86 [95% CI: −1.16, −0.55] in 24 h and SMD = −0.64 [95% CI: −0.84, −0.43] in 48 h), diode laser therapy (SMD = −0.27 [95% CI: −0.50, −0.04] in 48 h) and photodynamic therapy (SMD = −1.12 [95% CI: −2.18, −0.05] in 24 h). For postoperative pain incidence, a significant correlation was observed with reduced pain incidence rates in the photodynamic therapy group (pooled RR = 0.47 [95% CI: 0.31, 0.72]) but not in the low‐level laser therapy group (RR = 0.89 [95% CI: 0.30, 2.70] at 12 h and RR = 0.57 [95% CI: 0.09, 3.72] at 24 h).Conclusions: High‐quality evidence suggests that laser adjuvant therapies such as low‐level laser therapy, diode laser therapy and photodynamic therapy have a positive impact on reducing postoperative endodontic pain intensity. However, the differences in PEP management effects between laser therapies are unknown, and no significant differences were observed among the subgroups.Registration: CRD 42023402872 (PROSPERO).
- Open Access
- 23 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1065004
The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis
Background: Microbiome dysbiosis is considered a predictive biomarker of clinical response in renal cell carcinoma (RCC), which can be regulated by antibiotics (ATB). Multiple studies have shown that concomitant ATB administration has inhibitory effects on immunotherapy in RCC. This review aimed to assess the impact of ATB on patient survival and tumor response in RCC with immunotherapy.Methods: Literature evaluating the effect of ATB on immunotherapy in RCC from Cochrane Library®, PubMed®, Embase®, Scopus®, and Web of Science® were systematically searched. Hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for objective response rate (ORR) and primary progressive disease (PD) were pooled as effect sizes for clinical outcomes. Subgroup analysis was conducted to reveal the determinants of the effect of ATB on immunotherapy, including time windows of ATB exposure to immunotherapy initiation, ICIs treatment and study location. The leave-one-out approach was adopted to analyze the heterogeneity formulated. Cumulative meta-analysis adding by time was used to observe dynamic changes of the results.Results: Ten studies were included in the systematic review and six studies (with n=1,104 patients) were included in the meta-analysis, four studies were excluded for overlapping patients with subsequent larger studies and lack of unique patient-level data. ATB administration was significantly correlated with shorter PFS (HR=2.10, 95%CI [1.54; 2.85], I2 = 2% after omitting study Derosa et al, 2021 detected by leave-one-out approach), shorter OS (HR=1.69, 95%CI [1.34; 2.12], I2 = 25%) and worse ORR (OR=0.58, 95%CI [0.41; 0.84]), but no difference was observed in risk of PD (OR=1.18, 95%CI [0.97; 1.44]). No significant differences existed among the subgroups for determining the determinants of ATB inhibition.Conclusions: Concomitant ATB with immunotherapy was associated with worse PFS, OS and ORR in RCC. No publication bias was observed in this study.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=349577, identifier CRD42022349577.
- 23 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1065004
Open AccessThe negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis
Background: Microbiome dysbiosis is considered a predictive biomarker of clinical response in renal cell carcinoma (RCC), which can be regulated by antibiotics (ATB). Multiple studies have shown that concomitant ATB administration has inhibitory effects on immunotherapy in RCC. This review aimed to assess the impact of ATB on patient survival and tumor response in RCC with immunotherapy.Methods: Literature evaluating the effect of ATB on immunotherapy in RCC from Cochrane Library®, PubMed®, Embase®, Scopus®, and Web of Science® were systematically searched. Hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for objective response rate (ORR) and primary progressive disease (PD) were pooled as effect sizes for clinical outcomes. Subgroup analysis was conducted to reveal the determinants of the effect of ATB on immunotherapy, including time windows of ATB exposure to immunotherapy initiation, ICIs treatment and study location. The leave-one-out approach was adopted to analyze the heterogeneity formulated. Cumulative meta-analysis adding by time was used to observe dynamic changes of the results.Results: Ten studies were included in the systematic review and six studies (with n=1,104 patients) were included in the meta-analysis, four studies were excluded for overlapping patients with subsequent larger studies and lack of unique patient-level data. ATB administration was significantly correlated with shorter PFS (HR=2.10, 95%CI [1.54; 2.85], I2 = 2% after omitting study Derosa et al, 2021 detected by leave-one-out approach), shorter OS (HR=1.69, 95%CI [1.34; 2.12], I2 = 25%) and worse ORR (OR=0.58, 95%CI [0.41; 0.84]), but no difference was observed in risk of PD (OR=1.18, 95%CI [0.97; 1.44]). No significant differences existed among the subgroups for determining the determinants of ATB inhibition.Conclusions: Concomitant ATB with immunotherapy was associated with worse PFS, OS and ORR in RCC. No publication bias was observed in this study.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=349577, identifier CRD42022349577.